Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S
Tamar Kinaciyan, Emel Aygören-Pürsün, Inmaculada Martinez-Saguer, Daniel F. Soteres, Daisuke Honda, Michael E. Manning, H. James Wedner, Atsushi Fukunaga, Henry J. Kanarek, Kazumasa Ohmura, Isaac Melamed, Tariq El-Shanawany, Laurence Bouillet, William R. Lumry, Marc A. Riedl, Majed Koleilat, Bob Geng, Isao Ohsawa, Noemi Bara, Syed Rehman, Jonathan A. Bernstein, Paula J. Busse, Mauro Cancian, Danny M. Cohn, Timothy J. Craig, Henriette Farkas, Sorena Kiani-Alikhan, H. Henry Li, Jason P. Raasch, Raffi Tachdjian, Paul K. Audhya, Paolo Bajcic, Ya-Hsiu Chuang, Matthew Iverson, Michael D. Smith, Christopher M. Yea, Andrea Zanichelli · 2026
Read Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S by Tamar Kinaciyan, Emel Aygören-Pürsün, Inmaculada Martinez-Saguer, Daniel F. Soteres, Daisuke Honda, Michael E. Manning, H. James Wedner, Atsushi Fukunaga, Henry J. Kanarek, Kazumasa Ohmura, Isaac Melamed, Tariq El-Shanawany, Laurence Bouillet, William R. Lumry, Marc A. Riedl, Majed Koleilat, Bob Geng, Isao Ohsawa, Noemi Bara, Syed Rehman, Jonathan A. Bernstein, Paula J. Busse, Mauro Cancian, Danny M. Cohn, Timothy J. Craig, Henriette Farkas, Sorena Kiani-Alikhan, H. Henry Li, Jason P. Raasch, Raffi Tachdjian, Paul K. Audhya, Paolo Bajcic, Ya-Hsiu Chuang, Matthew Iverson, Michael D. Smith, Christopher M. Yea, Andrea Zanichelli (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13355760.txt.
Description
Tamar Kinaciyan and co-authors report interim results in 2026 from KONFIDENT-S, a long-term study of oral sebetralstat for swelling attacks in hereditary angioedema. Even on preventive therapy, patients still get breakthrough attacks of painful, sometimes dangerous swelling. Thirty-five patients on one of three preventive drugs treated 382 attacks with the study drug and tracked relief times.
Patients took the drug a median of six minutes after spotting an attack. Relief began at a median of about one hour, severity fell by about four hours, and attacks fully ended at about fifteen hours. Results were much like across all three preventive drugs, and no serious treatment-linked harms appeared.
Catalog record
| CREATOR | Tamar Kinaciyan, Emel Aygören-Pürsün, Inmaculada Martinez-Saguer, Daniel F. Soteres, Daisuke Honda, Michael E. Manning, H. James Wedner, Atsushi Fukunaga, Henry J. Kanarek, Kazumasa Ohmura, Isaac Melamed, Tariq El-Shanawany, Laurence Bouillet, William R. Lumry, Marc A. Riedl, Majed Koleilat, Bob Geng, Isao Ohsawa, Noemi Bara, Syed Rehman, Jonathan A. Bernstein, Paula J. Busse, Mauro Cancian, Danny M. Cohn, Timothy J. Craig, Henriette Farkas, Sorena Kiani-Alikhan, H. Henry Li, Jason P. Raasch, Raffi Tachdjian, Paul K. Audhya, Paolo Bajcic, Ya-Hsiu Chuang, Matthew Iverson, Michael D. Smith, Christopher M. Yea, Andrea Zanichelli |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56673 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |